Aktie A0NHD5 CARNA BIOSCIENCES, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Carna Biosciences, Inc.

Aktien

A0NHD5

JP3220550002

4572

Markt geschlossen - Japan Exchange
Andere Börsenplätze
 08:00:00 20.05.2024 		% 5 Tage % 1. Jan.
426 JPY -2,29 % Intraday Chart für Carna Biosciences, Inc. +0,95 % -18,39 %
07.03. Fresh Tracks Therapeutics, Inc. und Carna Biosciences, Inc. schließen Vereinbarung zur Beendigung der Lizenz ab CI
2023 Carna Biosciences, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Fresh Tracks Therapeutics, Inc. and Carna Biosciences, Inc. Enters into Termination of License Agreement
Carna Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Carna Biosciences, Inc. announced that it has received ¥11.209315 million in funding from Cantor Fitzgerald & Co.
Carna Biosciences, Inc. announced that it expects to receive Ñ11.209315 million in funding from Cantor Fitzgerald & Co.
Carna Biosciences, Inc. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022
Brickell Biotech Obtains Exclusive Rights to Carna Biosciences' Inhibitor Portfolio Targeting Inflammatory Diseases
Brickell Biotech, Inc. Enters into an Exclusive License Agreement with Carna Biosciences, Inc
Carna Biosciences, Inc. Reports Consolidated Earnings Results for the Six Months Ended June 30, 2021
Carna Biosciences, Inc. Provides Earnings Guidance for Full Year Ending December 31, 2021
Carna Biosciences, Inc. announced that it has received ¥14.67507 million in funding from Cantor Fitzgerald & Co.
Carna Biosciences, Inc. announced that it expects to receive ¥14.67507 million in funding from Cantor Fitzgerald & Co.
Carna Biosciences, Inc. Reports Consolidated and Non-Consolidated Earnings Results for the Year Ended December 31, 2020
Carna Biosciences, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2020
Carna Biosciences, Inc. Reports Consolidated Earnings Results for the Nine Months Ended September 30, 2020
Carna Biosciences, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2020
Carna Biosciences, Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2020
Carna Biosciences, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2020
Carna Biosciences, Inc. Announces Consolidated and Non-Consolidated Earnings Results for the Year Ended December 31, 2019; Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2020
Carna Biosciences, Inc. Provides Earnings Forecast for the Fiscal Year Ending December 31, 2019
Open Orphan Signs Contract with Carna Bioscience
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A0NHD5 Aktie
  4. Nachrichten Carna Biosciences, Inc.
  5. Andere Sprachen